

Coronavirus Disease 2019 (COVID-19) Situation Report



Weekly Report No. 225 - Saudi Arabia

28 January - 03 February, 2021

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Current	103,362,039	2,244,713	5,734,663	135,359
Last Week	99,864,391	2,149,700	5,576,021	132,166
In 7 days	3,497,648	95,013	158,642	3,193

Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	368,945	360,400	6,386	2,159	379	12,443,956
In 7 days	1,922	1,855	23	-	-	315,561
27/1/21	253	208	3	2,157	362	45,115
28/1/21	267	253	2	2,169	355	48,445
29/1/21	270	293	4	2,142	352	36,768
30/1/21	261	274	3	2,126	362	36,964
31/1/21	255	266	4	2,111	371	44,496
01/02/21	310	271	4	2,146	375	52,176
02/02/21	306	290	3	2,159	379	51,597

HIGHLIGHTS

- Regions with the highest new infections over the past 7 days: Riyadh (726), Eastern (432), Makkah (324), Madinah (79), Asir (67), Al Qassim (55), Northern Borders (54), and Al Bahah (52).
- Ministry of Interior: Suspending all events and parties for 30 extendable days (the maximum number of gatherings shall not exceed 20 persons), and closing cinemas, restaurants, shopping malls, gyms and sports centers for the next 10 days starting from 10 pm on Thursday, February 4.
- MoH: Pfizer vaccine company to resume the supply from the middle of February. More than 440,000 people have received the vaccine so far.
- It has been made mandatory for all Saudi citizens and expatriates to activate (Tawakkalna App) to prove their health status before entering public utilities and commercial complexes. Penalties against violating establishments will be imposed immediately on non-compliant markets, restaurants and establishments.
- Saudi Arabia suspends entry for non-citizens from 20 countries (Argentina, UAE, Germany, US, Indonesia, Ireland, Italy, Pakistan, Brazil, Portugal, UK, Turkey, South Africa, Sweden, Switzerland, France, Lebanon, Egypt, India and Japan) starting from 9 p.m. on Wednesday Feb.3. except diplomats, and medical staff and their families. Saudi Arabia has extended the travel ban for its citizens to May 17 instead of March 31.
- WHO publishes new Essential Diagnostics List and urges countries to prioritize investments in testing.
- WHO updated clinical case management guideline for COVID-19.
- WHO provides Interim recommendations for use of the Moderna COVID-19 vaccine, see link.
- WHO publishes Interim recommendations for the use of the Pfizer–BioNTech COVID-19 vaccine, under Emergency Use Listing, see link.
- WHO developed an online global consultation on contact tracing in the context of COVID-19, see link.
- Draft landscape and tracker of COVID-19 candidate vaccines, see link.
- WHO recommends follow-up care, low-dose anticoagulants for COVID-19 patients, see link

IMPORTANT LINKS





- **MoH COVID-19 updates:** <https://twitter.com/saudimoh>
- **WHO's COVID-19 global situation reports:** <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- **WHO's COVID-19 dashboard:** <https://covid19.who.int/>
- **MoH COVID-19 dashboard:** <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- **WHO's new essential diagnostics list:** <https://www.who.int/news/item/29-01-2021-who-publishes-new-essential-diagnostics-list-and-urges-countries-to-prioritize-investments-in-testing>
- **WHO's COVID-19 Clinical management living guidance:** <https://www.who.int/news/item/29-01-2021-who-publishes-new-essential-diagnostics-list-and-urges-countries-to-prioritize-investments-in-testing>
- **Interim recommendations for use of the Moderna vaccine:** <https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19>
- **Background document on the Pfizer–BioNTech vaccine:** [https://www.who.int/publications/i/item/background-document-on-mrna-vaccinebnt162b2-\(pfizer-biontech\)-against-covid-19](https://www.who.int/publications/i/item/background-document-on-mrna-vaccinebnt162b2-(pfizer-biontech)-against-covid-19)
- **Online global consultation on contact tracing in the context of COVID-19:** <https://www.who.int/publications/i/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- **Draft landscape and tracker of COVID-19 candidate vaccines:** <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
- **WHO recommends follow-up care, low-dose anticoagulants for COVID-19 patients:** <https://www.who.int/news-room/feature-stories/detail/who-recommends-follow-up-care-low-dose-anticoagulants-for-covid-19-patients>

IMPORTANT DEVELOPMENTS

WHO provides interim guidance on the use of the Moderna COVID-19 vaccine:

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021. The mRNA-1273 vaccine against COVID-19 developed by Moderna (Moderna COVID-19 vaccine) has been shown to have an efficacy of 94.1%, based on a median follow-up of two months. High efficacy was maintained across all age groups (above 18 years), and was not affected by sex or ethnicity. The data reviewed by WHO at this time support the conclusion that the known and potential benefits of the vaccine outweigh the known and potential risks. Intended use: Persons aged 18 years and above. The recommended schedule is two doses (0.5 ml each) given intramuscularly into the deltoid muscle. An interval of 28 days between doses is recommended. There is currently no evidence on the need for a booster dose or booster doses of the vaccine after the current two-dose vaccine series is complete. There should be a minimum interval of 14 days between administration of this vaccine and any other vaccine. A history of anaphylaxis to any component of the vaccine is a contraindication to vaccination. If anaphylaxis occurs after the first dose, a second dose of the Moderna vaccine or of the Pfizer/BioNTech should not be administered. Vaccination is recommended for older persons and persons with comorbidities. As with the Pfizer/BioNTech vaccine, mitigation measures (including use of face masks, physical distancing, handwashing) should continue to be followed by vaccinated individuals.

Vaccination logistics: The vaccine is provided as a frozen suspension at $-25\text{ }^{\circ}\text{C}$ to $-15\text{ }^{\circ}\text{C}$ in a multidose vial containing 10 doses. The vaccine must be thawed prior to administration. After thawing, vials can be stored refrigerated at $2\text{--}8\text{ }^{\circ}\text{C}$ for up to 30 days prior to withdrawal of the first dose. Unopened vials may be stored for up to 12 hours in cool storage or at room temperature ($8\text{--}25\text{ }^{\circ}\text{C}$). After the first dose has been withdrawn, the vial should be held between $2\text{ }^{\circ}\text{C}$ and $25\text{ }^{\circ}\text{C}$ and discarded after 6 hours. For more details, see link.



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa